Organovo Holdings (OTC: ONVO) hit the wall hard on June 27, 2012, falling a dreadful 58%. The company, which focuses on 3D bioprinting technology, had been having a successful June, reaching a high of $9.70 on June 18, 2012. This kind of sudden fall creates a disillusioned public. It begs the question, “Will the stock bounce?”
On May 21, 2012 the company announced the appointment of Michael David as Chief Strategy Officer. David has spent a lengthy amount of time in the industry already. He was most recently an associate partner at McKinsey & Company, where he did work in equity, pharmaceutical, biotech and diagnostics. With such a track record, David appears to be a perfect fit for Organovo Holdings. However, a new high-profile member typically brings in the potential of risk. Can Michael David get the company to the next level? Does he have the experience in the fast-changing biotechnology market?
Organova Holdings focuses on the developing of ‘bioprinting’. Bioprinting is the ability to create functional 3D tissues in way that the projections can be used for human disease research, drug discovery and the eventual therapies. The good thing for Organova is that their bioprinting technology has already established itself as a relevancy within the industry. In fact, many pharmaceutical companies have already begun using 3D projections to advance their own trials and testing. As reported by Reuters, CEO Keith Murphy has his full support in David and believes his expertise can bring the company’s products to a new level of success.
All of this sounds very promising – so why the recent fall?
There is always some ‘silver lining’ when a company’s stock falls from such great heights. Usually, it means that either a) the industry itself is suffering, or b) a flaw in the technology or service has been unveiled and noticed by the public
The good thing for Organova is that the answer isn’t ‘b’. The company’s technology has not been found unworthy and doesn’t possess any obvious flaws. Moreover, the bioprinting technology is the greatest aspect and asset of the company. As noted in a report from www.stockreads.com, there is a strong likely hood that the stock will bounce. Considering the fact that in 2010 TIME Magazine named the bioprinting technology one of the ‘Best Inventions of 2010’ and you can see the support and hype is there.
On June 28, 2012 the stock bounded back up to $4.25, a solid 15%. To gain a better perspective of the ‘flow’ of stock that the company has experienced consider the following:
- On May 25, 2012 the stock closed at $3.30
- On May 31, 2012 the stock closed at $4.50
- On June 5, 2012 the sock closed to $5.50
- On June 12, 2012 the sock closed at $5.97
- On June 20, 2012 the stock closed at $9.25
The following trend appears to indicate that the recent fall has nothing to do with Michael David; on the other hand, it appears he has done his job extraordinary well.
The biotechnology industry is one that is very much untested and risky. New technologies are patented on a daily basis, meaning the future will be full of untold surprises. Falls may occur – and they may be significant. However, when it comes to biotech, the sky’s the limit.
Please make sure to read and completely understand our disclaimer at https://www.wallstreetpr.com/disclaimer. While reading this article one must assume that we may be compensated for posting this content on our website.